Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,856
Completed, industry sponsors, Infectious disease and vaccines, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,856
1,856 trials
Showing 1 to 25, recently updated first.
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05630820 · 857 participants · Start Dec 6, 2022 · Primary completion Nov 3, 2025
Drug: Bepirovirsen; Placebo · For: Chronic Hepatitis B; Hepatitis B, Chronic
Sites: Centreville, Alabama; Los Angeles, California; San Francisco, California · 171 sites in all
- A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.Pivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT05246137 · 2,661 participants · Start Feb 3, 2022 · Primary completion Mar 3, 2023
Drug: COVID-19 Vaccine 40 ug/dose · For: SARS-CoV-2 Infection
Sites: Milan, Italy; Badalona, Spain; Barcelona, Spain · 18 sites in all
- Safety and Immunogenicity of a Booster Vaccination With an Adapted VaccinePivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT06181292 · 913 participants · Start Nov 15, 2023 · Primary completion Jun 17, 2024
Drug: PHH-1V81; Comirnaty Omicron XBB1.5 · For: SARS-CoV2 Infection
Sites: Badalona, Spain; Barcelona, Spain; Centelles, Spain · 10 sites in all
- A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.Pivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT05303402 · 240 participants · Start May 12, 2022 · Primary completion Jan 9, 2024
Drug: PHH-1V · For: SARS CoV 2 Infection
Sites: Badalona, Spain; Barcelona, Spain; Girona, Spain · 6 sites in all
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19Pivotal-lookingCompleted
ShionogiIndustry
NCT05305547 · 2,093 participants · Start Aug 3, 2022 · Primary completion Jan 7, 2024
Drug: S-217622; Placebo · For: SARS-CoV-2 Infection
Sites: Guntersville, Alabama; Tempe, Arizona; Tucson, Arizona · 196 sites in all
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgePivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT07365826 · 1,390 participants · Start Jan 12, 2026 · Primary completion Oct 21, 2026
Drug: 31-valent pneumococcal conjugate vaccine; Seasonal Influenza Vaccine (SIV) (Flublok) and 1 more · For: Pneumococcal Disease
Sites: Phoenix, Arizona; Fort Collins, Colorado; DeLand, Florida · 25 sites in all
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationPivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT07425392 · 752 participants · Start Feb 9, 2026 · Primary completion Oct 25, 2026
Drug: 31-valent pneumococcal conjugate vaccine; PCV20 · For: Pneumococcal Disease
Sites: Chinle, Arizona; Phoenix, Arizona; Whiteriver, Arizona · 30 sites in all
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenPivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT07211152 · 150 participants · Start Oct 13, 2025 · Primary completion Jun 26, 2026
Drug: Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV; Vaxigrip QIV · For: Influenza
Sites: Mandaluyong, Philippines; Manila, Philippines
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)Pivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT06768671 · 35 participants · Start Dec 30, 2024 · Primary completion Sep 28, 2026
Drug: Sonelokimab · For: Hidradenitis Suppurativa
Sites: North Little Rock, Arkansas; Stanford, California; Washington D.C., District of Columbia · 18 sites in all
- Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07229820 · 157 participants · Start Nov 8, 2025 · Primary completion Dec 22, 2025
Drug: ZSP1273; Placebo · For: Influenza A
Sites: Shanghai, China
- A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and OlderPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06551181 · 2,620 participants · Start Aug 5, 2024 · Primary completion Apr 24, 2025
Drug: RSVPreF3 OA investigational vaccine; Placebo (Saline solution) · For: Respiratory Syncytial Virus Infections
Sites: Shanghai, China; Espoo, Finland; Helsinki, Finland · 40 sites in all
- Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07229807 · 120 participants · Start Nov 22, 2025 · Primary completion Jan 17, 2026
Drug: ZSP1273; Oseltamivir · For: Influenza a
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT05620836 · 619 participants · Start Feb 22, 2023 · Primary completion Jan 7, 2025
Drug: Povorcitinib; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Scottsdale, Arizona; Arkansas City, Arkansas; Fayetteville, Arkansas · 101 sites in all
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVPivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06868264 · 940 participants · Start Apr 7, 2025 · Primary completion Jun 18, 2026
Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR); Sofosbuvir-Velpatasvir (SOF/VEL) · For: HEPATITIS C VIRUS CHRONIC INFECTION
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 105 sites in all
- A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized InfantsPivotal-lookingCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT06775405 · 180 participants · Start Feb 29, 2024 · Primary completion Apr 7, 2025
Drug: AK0529; Placebo · For: Respiratory Synctial Virus Infections
Sites: Beijing, China; Changchun, China; Changsha, China · 17 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04242446 · 505 participants · Start Feb 19, 2020 · Primary completion Apr 7, 2022
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 88 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04242498 · 509 participants · Start Mar 2, 2020 · Primary completion Nov 9, 2021
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Thousand Oaks, California; Miami, Florida · 91 sites in all
- Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold TreatmentPivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT05118672 · 567 participants · Start Mar 26, 2025 · Primary completion Aug 26, 2025
Drug: Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg); Placebo · For: Cold; Flu Symptom
Sites: São Paulo, Brazil; Sorocaba, Brazil
- Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal CandidiasisPivotal-lookingCompleted
pH-D Feminine Health LLCIndustry
NCT07109869 · 333 participants · Start Aug 8, 2025 · Primary completion Aug 12, 2026
Drug: Boric acid · For: Vulvovaginal Candidiases; Vulvovaginal Candidiasis, Genital; Vulvovaginal Candidiasis (VVC)
Sites: Mobile, Alabama; Little Rock, Arkansas; Huntington Park, California · 26 sites in all
- Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus LoratadinePivotal-lookingCompleted
Laboratorios Silanes S.A. de C.V.Industry
NCT06531707 · 177 participants · Start Jun 24, 2024 · Primary completion Jan 20, 2025
Drug: Ibuprofen + Loratadine fixed dose; Ibuprofen and 1 more · For: Common Cold
Sites: Mexico City, Mexico
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT07135986 · 1,602 participants · Start Sep 26, 2025 · Primary completion May 1, 2026
Drug: MenACYW conjugate vaccine; MenACYW135 polysaccharide vaccine and 1 more · For: Meningococcal Infection; Healthy Volunteers
Sites: Nanning, China; Jingxi, China; Liuzhou, China · 4 sites in all
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Pivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT07284654 · 4,049 participants · Start Dec 1, 2025 · Primary completion Sep 17, 2026
Drug: 31 valent pneumococcal conjugate vaccine; PCV20 and 1 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Chinle, Arizona; Whiteriver, Arizona · 30 sites in all
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgePivotal-lookingCompleted
BioNTech SEIndustry
NCT07300839 · 5,240 participants · Start Dec 10, 2025 · Primary completion Sep 22, 2026
Drug: BNT162b2 Vaccine; Placebo · For: COVID-19; SARS-COV-2 Infection
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 196 sites in all
- Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in ChinaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05110261 · 800 participants · Start Nov 24, 2021 · Primary completion Nov 24, 2025
Drug: Nirsevimab; Placebo · For: Lower Respiratory Tract Infection
Sites: Beijing, China; Changde, China; Changsha, China · 30 sites in all
- HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2Pivotal-lookingCompleted
Huahui HealthIndustry
NCT05787418 · 918 participants · Start Mar 31, 2023 · Primary completion Mar 27, 2024
Drug: HH-120 Nasal Spray; Placebo · For: COVID-19
Sites: Beijing, China; Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.